

Divi's Laboratories Limited

Date: May 20, 2023

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

To
The Secretary **BSE Limited**Phiroze Jeejeebhoy Towers,
Dalal Street **MUMBAI – 400 001**

Stock Code: DIVISLAB Stock Code: 532488

Dear Sir / Madam,

Sub: Disclosure of related party transactions for the half year ended March 31, 2023

Ref: Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose disclosure of Related Party Transactions in the specified format for the half year ended March 31, 2023.

This is for your information and records.

Thanking You,
Yours faithfully,
For Divi's Laboratories Limited

M. Satish Choudhury Company Secretary & Compliance Officer

Regd. Off.: Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA. Tel: +91-40-6696 6300/400. Fax: 91-40-6696 6460.. CIN: L24110TG1990PLC011854

E-mail: mail@divislabs.com, Website: www.divislabs.com

DIVI'S LABORATORIES LIMITED

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED 31.03.2023

(In accordance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

(in Rs. lakhs) Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. In case any financial indebtedness is Details of the loans, inter-corporate deposits, advances or investments In case monies are due to incurred to make or give loans, inter-Details of the party (listed either party as a result of corporate deposits, advances or S. No entity /subsidiary) entering Details of the counterparty investments into the transaction the transaction Purpose for which Value of the Value of Nature of Nature (loan/ the funds will be related party indebtedness transaction Opening Closing advance/ inter Relationship of the counterparty with the ecured/ utilised by the Type of related party transaction transaction as during the balance As balance As (loan/ issuance Name Name Cost Tenure corporate Tenure listed entity or its subsidiary Rate (%) ultimate recipient approved by the on 01/10/2022 on 31/3/2023 of debt/ any deposit/ reporting of funds (endaudit committee period other etc.) investment usage) Salary, allowances & remuneration 1 Divi's Laboratories Limited Dr. Murali. K. Divi Key Management Personnel 2,768.31 4,265.86 7,015.99 based on net profits Salary, allowances & remuneration 2 Divi's Laboratories Limited Mr NV Ramana 1,437.08 2.136.31 3,513,77 Key Management Personnel based on net profits 3 Divi's Laboratories Limited Mr. Madhusudana Rao Divi Key Management Personnel Salary & allowances 57.74 5.00 6.01 Salary, allowances & remuneration 4 Divi's Laboratories Limited Dr. Kiran S. Divi Key Management Personnel based on net profits 984.75 1,426.49 2,339.77 Salary, allowances & remuneration 5 Divi's Laboratories Limited Ms. Nilima Prasad Divi Key Management Personnel based on net profits 985.58 1,426.55 2,340.13 6 Divi's Laboratories Limited Mr. K.V.K. Seshavataram Non-Executive Director Sitting Fee & Annual Remuneration 15.00 10.00 7 Divi's Laboratories Limited Mr. R. Ranga Rao Sitting Fee & Annual Remuneration 17.00 Non-Executive Director 10.00 8 Divi's Laboratories Limited Dr. G. Suresh Kumar Non-Executive Director Sitting Fee & Annual Remuneration 16.00 10.00 9 Divi's Laboratories Limited Dr. Ramesh B. V. Nimmagadda Non-Executive Director Sitting Fee & Annual Remuneration 16.00 10.00 10 Divi's Laboratories Limited Non-Executive Director Sitting Fee & Annual Remuneration 14.00 10.00 Dr. S. Ganapaty 11 Divi's Laboratories Limited Prof. Sunaina Singh Non-Executive Director Sitting Fee & Annual Remuneration 11.00 10.00 Mr K.V. Chowdary Non-Executive Director 12 Divi's Laboratories Limited Sitting Fee & Annual Remuneration 14.00 10.00 Mr. L. Kishore Babu Key Management Personnel 13 Divi's Laboratories Limited Salary & allowances 165.00 14.99 14 Divi's Laboratories Limited Mr. M. Satish Choudhury Key Management Personnel Salary & allowances 19 35 2.26 3.08 15 Divi's Laboratories Limited Mr. N.V.Anirudh Relative of Key Management Personnel Salary & allowances 10.26 9.64 1.00 2.28 16 Divi's Laboratories Limited Mr. L. Ramesh Babu Relative of Key Management Personnel Salary & allowances 121.00 121.00 11.07 18.96 Entities in which Key Management Personne 17 Divi's Laboratories Limited Divi's Properties Private Limited have Significant Influence Building rent 467.91 467.91 Entities in which Key Management Personnel 18 Divi's Laboratories Limited Divi's Biotech Private Limited 8.94 8.94 2.40 have Significant Influence Rent Entities in which Key Management Personnel 19 Divi's Laboratories Limited Divi's Properties Private Limited 342 00 have Significant Influence Rent Deposit 342.00 20 Divi's Laboratories Limited Divis Laboratories (USA) Inc Subsidiary Company Sales Not Applicable 8,878.91 10,217.59 10,521.44 Subsidiary Company 21 Divi's Laboratories Limited Divi's Laboratories Europe AG Sales Not Applicable 6,734.36 18,210.60 18,716.15 22 Divi's Laboratories Limited Divis Laboratories (USA) Inc Subsidiary Company Purchases Not Applicable 11.00 23 Divis Laboratories (USA) Inc Divi's Laboratories Europe AG Subsidiaries of Divi's Laboratories Limited 632.99 302.00 Sales Not Applicable

Not Applicable

2,348,00

1,088,84

83.00

Subsidiaries of Divi's Laboratories Limited

Sales

24 Divi's Laboratories Europe AG Divis Laboratories (USA) Inc

^{1. * -} As per the Companies Act, 2013 / approval of Board of Directors or shareholders according to the statutory requirment.

^{2.} The remuneration to key managerial person does not include the provision made for gratuity and compensated absences, as they are on actuarial basis for the Company as a whole.

^{3.} The PAN details are not to be included in the disclosure pursuant to guidance note issued by the stock exchanges.